FDA and Border Officials Join Forces to Seize Vast Quantity of Illegal E-Cigarettes
Medically reviewed by Drugs.com.
By Stephanie Brown HealthDay Reporter
THURSDAY, May 22, 2025 -- In February of this year, the U.S. Food and Drug Administration and U.S. Customs and Border Protection seized nearly 2 million units of unauthorized electronic cigarette products in Chicago.
The operation was a joint federal effort from the FDA and CBP to intercept incoming shipments and prevent the entry of illegal e-cigarettes into the United States. The estimated retail value of this seizure was $33.8 million.
Almost all of the illegal e-cigarette products discovered by the team originated in China and were intended for shipment to multiple U.S. states. Officials from the two agencies said that numerous unauthorized e-cigarette shipments have been entering the country and seem to suggest an attempt to avoid duty fees and import safety reviews. Specifically, these shipments often feature unclear product descriptions and inaccurate declared values.
"We continue to see an increased number of shipments of vaping-related products packaged and mislabeled to avoid detection," Bret Koplow, Ph.D., J.D., acting director of the FDA Center for Tobacco Products, said in a statement. "However, we have been successful at preventing these shipments from entering the U.S. supply chain -- despite efforts to conceal the true identity of these unauthorized e-cigarette products."
None of the e-cigarette products confiscated had the necessary premarket authorization orders from the FDA. As a result, these products cannot be legally marketed or distributed within the United States. All products seized in this latest impoundment are expected to be destroyed.
Seven hundred and fifty warning letters have been sent to manufacturers, sellers, and distributors as part of the FDA enforcement actions against unauthorized new tobacco products. In addition, 800 warning letters have been issued to retailers. The agency has filed civil money penalty complaints against 87 manufacturers and more than 175 retailers for their involvement in the distribution or sale of these items.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-05-23 12:00
Read more

- Chimpanzees' Drumming May Be Ancient Form of Communication
- FDA Grants Interchangeable Designation to Fresenius Kabi’s Biosimilar Otulfi (ustekinumab-aauz)
- Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST - Modifier Gene Therapy for the Treatment of Stargardt Disease
- Gabapentinoids Not Directly Associated With Risk of Self-Harm
- FDA Approves Topical Foam for Plaque Psoriasis of the Scalp and Body
- Celltrion's Yuflyma (adalimumab-aaty) Receives FDA Interchangeability Designation for All Approved Dosage Forms and Strengths
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions